ArticleCurrent microbiology2022
Evaluation of the Active Ingredient of Campsis radicans Essential Oils and its Antimicrobial Evaluation Against Pathogenic Bacteria.
Article in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 8 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to the resistance of nosocomial pathogens to antibiotics, the need for herbal medicines is felt. The aim of this study was to identify the chemical composition of bark essential oils of Campsis radicans and the effect of its free and encapsulated form on resistant nosocomial pathogens. This plant is a native of Northern Iran. The Bark essential oils of Campsis radicans was first extracted and its antimicrobial effects were investigated. Then, its phytochemical compounds were determined using Gas Chromatography-Mass Spectrometry (GC/MS). Guaiacol (2-methoxy phenol) was selected as the active ingredient among 32 compounds (2.40%). It was encapsulated and the encapsulation efficiency (EE), the particle size, polydispersity index (pdi), Fourier transform infrared (FTIR), release, and stability were determined. Then, the antimicrobial effect of both free and encapsulated forms was evaluated on cotrimoxazole-resistant Pseudomonas aeruginosa, cefixime-resistant Escherichia coli, and fluconazole-resistant Candida albicans. It was observed that both free and encapsulated forms of Guaiacol had an antimicrobial effect on the studied resistant strains, but the encapsulated form had a more antimicrobial effect due to more stability and a more targeted effect. MBC (MFC) ranged from 0.270 to 0.439 µg/ml in the free form and from 0.055 to 0.133 µg/ml in the encapsulated form, EE was 86%, particle size, and pdi were 138 nm and 0.26, respectively. This study showed that this plant can be a suitable alternative to chemical drugs due to its antimicrobial effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.